Hexokinase 2 remained as an independent prognostic factor, which led us to further exploit the functional effects of the hexokinase 2 inhibitor 2-deoxy-D-glucose in “in vitro” and “in vivo” preclinical models of bladder cancer. Here, HK2 is linked to urinary bladder cancer.